WAVE Life Sciences (NASDAQ:WVE) Hits New 12-Month Low – What’s Next?

WAVE Life Sciences Ltd. (NASDAQ:WVE) hit a new 52-week low on Thursday . The company traded as low as $5.11 and last traded at $5.2590, with a volume of 11044062 shares traded. The stock had previously closed at $12.30.

Trending Headlines about WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Company press release: management highlighted six‑month, placebo‑adjusted improvements in body composition (240 mg single dose produced ~14% visceral fat reduction, ~5% total fat reduction, +2% lean mass, ~3.3% waist circumference reduction) and continued safety/tolerability — data that supports the therapy’s mechanism and future development plans. Wave press release
• Positive Sentiment: Management commentary / transcripts emphasize the visceral‑fat and body‑composition signal and durability at six months, which supporters point to as a differentiated outcome versus pure body‑weight endpoints. Seeking Alpha transcript
• Positive Sentiment: Analyst positioning remains mixed but includes continued conviction from some firms: Bank of America kept a Buy rating (PT cut), Wells Fargo kept Overweight (PT cut), Truist upgraded to Strong‑Buy and Mizuho issued bullish commentary — these voices can limit downside and attract buyers after the sell‑off. Benzinga (analyst notes)
• Neutral Sentiment: Independent outlets and investor notes characterize the data as “clinically interesting” on body composition but still early‑stage and not yet persuasive on meaningful weight loss — meaning future development and larger trials will determine value. ProactiveInvestors report
• Negative Sentiment: Market reaction: shares plunged >50% after investors focused on the modest ~0.9% body‑weight reduction at six months and the higher‑dose readout that “failed to show a clear improvement” by some measures — the gap between body‑composition signals and headline weight loss disappointed traders. Reuters
• Negative Sentiment: Investor/legal risk: a law firm is publicizing an investigation into potential claims by shareholders, adding litigation overhang and downward pressure on sentiment. GlobeNewswire (Johnson Fistel)
• Negative Sentiment: Analyst downgrades and target cuts followed the update; multiple outlets report steep target cuts and downgrades that reflect lower near‑term expectations and have likely amplified selling pressure. Seeking Alpha downgrade

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on WVE shares. UBS Group set a $32.00 price target on shares of WAVE Life Sciences in a report on Tuesday, December 16th. Wells Fargo & Company decreased their target price on shares of WAVE Life Sciences from $27.00 to $13.00 and set an “overweight” rating for the company in a research report on Friday. Royal Bank Of Canada upgraded shares of WAVE Life Sciences from a “sector perform” rating to an “outperform” rating and raised their target price for the company from $9.00 to $27.00 in a research note on Monday, December 8th. Canaccord Genuity Group lifted their price target on shares of WAVE Life Sciences from $43.00 to $52.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Finally, Citigroup upped their price target on WAVE Life Sciences from $16.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $31.38.

WAVE Life Sciences Stock Performance

The stock’s 50 day simple moving average is $12.93 and its 200-day simple moving average is $11.20. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -5.21 and a beta of -1.77.

WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.02). The company had revenue of $17.25 million for the quarter, compared to analyst estimates of $15.68 million. WAVE Life Sciences had a negative return on equity of 85.69% and a negative net margin of 478.35%. On average, analysts expect that WAVE Life Sciences Ltd. will post -1.14 EPS for the current fiscal year.

Insider Transactions at WAVE Life Sciences

In other WAVE Life Sciences news, CEO Paul Bolno sold 10,480 shares of WAVE Life Sciences stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $13.45, for a total transaction of $140,956.00. Following the completion of the sale, the chief executive officer owned 275,520 shares of the company’s stock, valued at approximately $3,705,744. The trade was a 3.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Kyle Moran sold 3,588 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $13.45, for a total value of $48,258.60. Following the completion of the transaction, the chief financial officer directly owned 134,385 shares in the company, valued at $1,807,478.25. This represents a 2.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 61,748 shares of company stock worth $907,809. 23.98% of the stock is owned by insiders.

Institutional Investors Weigh In On WAVE Life Sciences

A number of large investors have recently bought and sold shares of the company. CWM LLC raised its position in WAVE Life Sciences by 6,729.0% during the 4th quarter. CWM LLC now owns 2,117 shares of the company’s stock worth $36,000 after buying an additional 2,086 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of WAVE Life Sciences by 645.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company’s stock valued at $38,000 after acquiring an additional 1,942 shares during the last quarter. Bessemer Group Inc. boosted its holdings in shares of WAVE Life Sciences by 1,156.3% in the 3rd quarter. Bessemer Group Inc. now owns 9,925 shares of the company’s stock valued at $72,000 after acquiring an additional 9,135 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of WAVE Life Sciences by 1,441.6% in the third quarter. Russell Investments Group Ltd. now owns 9,928 shares of the company’s stock worth $73,000 after acquiring an additional 9,284 shares during the period. Finally, Ameritas Investment Partners Inc. increased its stake in shares of WAVE Life Sciences by 18.7% in the second quarter. Ameritas Investment Partners Inc. now owns 11,444 shares of the company’s stock worth $74,000 after acquiring an additional 1,802 shares during the period. Hedge funds and other institutional investors own 89.73% of the company’s stock.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.